Soliris and Thrombotic microangiopathy - a phase IV clinical study of FDA data

Summary:

Thrombotic microangiopathy is reported as a side effect among people who take Soliris (eculizumab), especially for people who are female, 30-39 old, have been taking the drug for < 1 month also take Bactrim, and have Haemolytic uraemic syndrome.

The phase IV clinical study analyzes which people have Thrombotic microangiopathy when taking Soliris. It is created by eHealthMe based on reports of 58,774 people who have side effects when taking Soliris from the FDA, and is updated regularly.

What is Soliris?

Soliris has active ingredients of eculizumab. It is often used in paroxysmal nocturnal hemoglobinuria (pnh). eHealthMe is studying from 58,821 Soliris users. Check the latest studies of Soliris.

What is Thrombotic microangiopathy?

Thrombotic microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury) is found to be associated with 469 drugs and 672 conditions by eHealthMe. Check the latest studies of Thrombotic microangiopathy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 23, 2026

58,774 people reported to have side effects when taking Soliris.
Among them, 724 people (1.23%) have Thrombotic microangiopathy.

Could Soliris cause Thrombotic microangiopathy?

Among these 724 people:

How long have people been on Soliris when they have Thrombotic microangiopathy? *

Click here to view more results

What is the gender of people who have Thrombotic microangiopathy when taking Soliris? *

Click here to view

What is the age of people who have Thrombotic microangiopathy when taking Soliris? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Soliris and have Thrombotic microangiopathy?

- Check whether Thrombotic microangiopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Soliris:

Soliris (58,821 reports)

Thrombotic microangiopathy treatments and more:

Thrombotic microangiopathy (11,852 reports)

How severe was Thrombotic microangiopathy and when was it recovered:

Thrombotic microangiopathy in Soliris

Expand to all the drugs that have ingredients of eculizumab:

Thrombotic microangiopathy and drugs with ingredients of eculizumab (862 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Soliris:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Thrombotic microangiopathy:

Thrombotic microangiopathy (469 drugs)

Browse all the conditions that are associated with Thrombotic microangiopathy:

Thrombotic microangiopathy (672 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on eculizumab (the active ingredients of Soliris) and Soliris (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.